联邦制药(03933)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

03933 联邦制药

休市中 08-21 16:08:08

9.010

+0.295

+3.38%

最高9.050	最低8.695	成交量1,442万
今开8.830	昨收8.715	日振幅4.07%
总市值177.50亿	流通市值177.50亿	总股本19.70亿
成交额1.28亿	换手率0.73%	流通股本19.70亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"03933","market":"HK","secType":"STK","nameCN":"联邦制药","latestPrice":9.01,"timestamp":1787299688008,"preClose":8.715,"halted":0,"volume":14424000,"delay":0,"changeRate":0.03384968445209408,"floatShares":1970000000,"shares":1970000000,"eps":1.2911610535642872,"marketStatus":"休市中","change":0.295,"latestTime":"08-21 16:08:08","open":8.83,"high":9.05,"low":8.695,"amount":128352820,"amplitude":0.040734,"askPrice":9.01,"askSize":16000,"bidPrice":9.005,"bidSize":8000,"shortable":3,"etf":0,"ttmEps":1.365258411812215,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1787535000000},"marketStatusCode":7,"adr":0,"listingDate":1181836800000,"exchange":"SEHK","adjPreClose":8.715,"dividendRate":0.053811,"openAndCloseTimeList":[[1787275800000,1787284800000],[1787288400000,1787299200000]],"volumeRatio":1.3152844404900121,"lotSize":2000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/03933","defaultTab":"news","newsList":[{"id":"2660442700","title":"联邦制药预计上半年净溢利同比降至约3.4亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2660442700","media":"财中社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660442700?lang=zh_cn&edition=full","pubTime":"2026-08-19 18:42","pubTimestamp":1787136120,"startTime":"0","endTime":"0","summary":"8月19日，联邦制药（03933）发布公告，公司预计2026年上半年净溢利约为3.4亿元，而去年同期则为18.93亿元。公告提到，净溢利减少受中间体产品及原料药分部的产品市场价格下行及需求调整的影响。此外，2026年上半年来自诺和诺德（NVO.N）许可费收入约1.01亿元，而去年同期则约为14.33亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608193846427450.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608193846427450.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IE00B3M56506.USD","03933","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133868975","title":"联邦制药（03933）发出盈利警告：上半年净利预计约3.4亿元，同比大幅下降","url":"https://stock-news.laohu8.com/highlight/detail?id=1133868975","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1133868975?lang=zh_cn&edition=full","pubTime":"2026-08-19 18:35","pubTimestamp":1787135744,"startTime":"0","endTime":"0","summary":"2026年8月19日，联邦制药国际控股有限公司发布盈利警告。根据集团截至2026年6月30日止六个月按香港财务报告准则编制的未经审计综合管理账目，预计期内净利润约为3.4亿元人民币，而上年同期净利润约为18.93亿元人民币。同时，来自Novo Nordisk A/S的许可费收入由2025年上半年的约14.33亿元人民币下降至2026年上半年的约1.01亿元人民币。联邦制药计划在即将发布的2026年中期业绩公告及中期报告中披露详尽业绩。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03933"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660440874","title":"联邦制药(03933.HK)发盈警 预计中期净溢利约3.4亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2660440874","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660440874?lang=zh_cn&edition=full","pubTime":"2026-08-19 18:28","pubTimestamp":1787135317,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["03933","BK1191","IE00B3M56506.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175075729","title":"联邦制药中期净利下滑 中间体及原料药板块量价齐跌所致","url":"https://stock-news.laohu8.com/highlight/detail?id=1175075729","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1175075729?lang=zh_cn&edition=full","pubTime":"2026-08-19 18:26","pubTimestamp":1787135200,"startTime":"0","endTime":"0","summary":"联邦制药国际控股有限公司（简称“联邦制药”）发布业绩报告显示，其上半年净利润出现明显回落。究其原因，主要归咎于中间体与大宗原料药两大业务板块所面临的价格疲软及需求不振的双重压力。市场环境的持续低迷，叠加产品售价的走低，直接侵蚀了公司的盈利空间。这一业绩变动，折射出制药行业细分领域当前所遭遇的阶段性挑战。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","03933","IE00B3M56506.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161075751","title":"联邦制药预计2026年上半年净利润3.4亿元，较2025年同期19.93亿元大幅下滑","url":"https://stock-news.laohu8.com/highlight/detail?id=1161075751","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1161075751?lang=zh_cn&edition=full","pubTime":"2026-08-19 18:26","pubTimestamp":1787135168,"startTime":"0","endTime":"0","summary":"联邦制药国际控股有限公司披露业绩预告，预计截至2026年6月30日止六个月录得净利润约人民币3.4亿元。对比来看，2025年同期该公司的净利润规模高达人民币19.93亿元，降幅令人瞩目。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03933","BK1191","IE00B3M56506.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659199950","title":"【券商聚焦】中信建投：AI制药大有可为，产业链有望持续受益","url":"https://stock-news.laohu8.com/highlight/detail?id=2659199950","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659199950?lang=zh_cn&edition=full","pubTime":"2026-08-14 08:58","pubTimestamp":1786669118,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券研究指出，AI制药领域正经历着快速的迭代和变革，算法的更新迭代和算力的支持为AI在制药领域的应用打下了良好的基础。传统药物开发过程花费时间长成本高，且成功率较低，随着已有靶点的新药陆续获批，新药开发难度逐渐上升。近年来AI特别是深度学习的发展，促进了其在包括靶点筛选、分子生成及优化、ADMET预测、晶型预测以及合成路线筛选等的应用，AI用于大分子药物的开发投入也持续增长。AIDD有望重塑早期药物发现的流程，大大加速早期药物筛选的效率及成功率，相关干实验投入的增加以及对湿实验需求持续的增长，有望为下游产业链持续带来增量。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250106/ZmQ4YWNjMjZmNDUwZDg4ZTlkYjEwZTY1NmI3NmEzMzkwOTI4OTA5.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/ZmQ4YWNjMjZmNDUwZDg4ZTlkYjEwZTY1NmI3NmEzMzkwOTI4OTA5.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1988188","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0634319403.HKD","LU1303224171.USD","BK1500","KCE","LU0348735423.USD","02367","LU0348783233.USD","LU1719994722.HKD","LU0540923850.HKD","601066","LU0348825331.USD","LU2476274308.USD","AGIX","LU0348784397.USD","LU0348827113.USD","LU0561508036.HKD","01099","ARTY","KURE","LU1770034418.SGD","BK1585","BK1515","LU1961090484.USD","LU2778985437.USD","LU0417516571.SGD","LU0828237510.HKD","QTOC","SG9999004311.SGD","IE00B5MMRT66.SGD","VTHR","CHAT","LU2476274720.SGD","02228","AIPO","LU0417516738.SGD","06160","01789","09926","LU0640798160.USD","LU0348766576.USD","BK1191","BK1197","01477","02268","01530","LU2328871848.SGD","03933","06821","09688","02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110719570","title":"联邦制药（03933）将于8月31日召开董事会审议中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1110719570","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1110719570?lang=zh_cn&edition=full","pubTime":"2026-08-13 16:45","pubTimestamp":1786610742,"startTime":"0","endTime":"0","summary":"联邦制药国际控股有限公司（03933）8月13日公告，公司董事会已排定于2026年8月31日（星期一）召开会议，议程包括审议并批准公司及其附属公司截至2026年6月30日止六个月的中期业绩，并讨论派发中期股息（如有）。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03933"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165811033","title":"联邦制药（03933）创新药UBT48128片获美国FDA临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1165811033","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1165811033?lang=zh_cn&edition=full","pubTime":"2026-08-11 18:11","pubTimestamp":1786443113,"startTime":"0","endTime":"0","summary":"2026年8月11日，联邦制药国际控股有限公司公告称，其全资附属公司联邦生物科技有限公司自主研发的1类创新药UBT48128片，针对超重或肥胖及2型糖尿病的两项新药临床试验注册申请已获美国食品药品监督管理局批准，IND编号分别为182060和182061。据披露，UBT48128片是一款小分子胰高血糖素样肽-1受体激动剂，可通过促进胰岛素分泌、控制食欲及调整能量代谢以降低血糖并减轻体重。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03933"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658990999","title":"联邦制药(03933)：UBT48128片获美国FDA临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2658990999","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658990999?lang=zh_cn&edition=full","pubTime":"2026-08-11 18:08","pubTimestamp":1786442924,"startTime":"0","endTime":"0","summary":"智通财经APP讯，联邦制药 发布公告，本公司全资附属公司联邦生物科技有限公司自主研发的1类创新药UBT48128片关于超重或肥胖适应症及2型糖尿病适应症的新药临床试验注册申请获美国食品药品监督管理局批准，IND编号分别为182060和182061。多种动物模型的临床前研究表明，UBT48128可显著降低体重和血糖，且减重效果优于目前已上市的同类产品。预期本产品将于超重或肥胖及2型糖尿病展现出良好的治疗获益前景。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478571.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00B3M56506.USD","BK1191","03933","BBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133069004","title":"联邦制药：UBT48128片获批临床试验，针对超重、肥胖及2型糖尿病","url":"https://stock-news.laohu8.com/highlight/detail?id=1133069004","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1133069004?lang=zh_cn&edition=full","pubTime":"2026-08-11 18:08","pubTimestamp":1786442892,"startTime":"0","endTime":"0","summary":"联邦制药（UNITED LAB）宣布，其研发的UBT48128片已获得美国食品药品监督管理局（FDA）批准，正式开展针对超重、肥胖及2型糖尿病的临床试验申请（IND）。这一进展标志着该药物在代谢疾病治疗领域迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","03933","IE00B3M56506.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133427303","title":"联邦制药2026年7月股份变动月报表：回购并注销275万股，注册股本保持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1133427303","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1133427303?lang=zh_cn&edition=full","pubTime":"2026-08-05 13:10","pubTimestamp":1785906635,"startTime":"0","endTime":"0","summary":"联邦制药国际控股有限公司于2026年8月5日发布了截至2026年7月31日止的证券变动月报表，宣布公司在报告期内进行了股份回购并注销操作，同时注册股本规模保持不变。根据公告，联邦制药的法定注册股本依旧为3,800,000,000股普通股，每股面值港币0.01元，合计注册股本仍为港币38,000,000，与上月相比无新增或减少。月报同时显示，联邦制药已满足并持续符合香港联合交易所有限公司的公众持股量要求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03933"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652447086","title":"联邦制药再收诺和诺德1350万美元里程碑款 ，6月启动Ⅲ期临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2652447086","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652447086?lang=zh_cn&edition=full","pubTime":"2026-07-17 14:13","pubTimestamp":1784268798,"startTime":"0","endTime":"0","summary":"7月16日，联邦制药发布公告，其附属公司联邦生物科技（珠海横琴）有限公司已于7月15日收取诺和诺德支付的UBT251注射液里程碑付款1350万美元（扣除丹麦预缴税后）。该笔款项对应UBT251超重或肥胖适应证的全球Ⅱ期临床里程碑。记者了解到，此次付款源于双方于去年3月订立的独家许可协议。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607173810959226.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607173810959226.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["03933","BK1191","IE00B3M56506.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651413669","title":"联邦制药：联邦生物科技已收取诺和诺德支付的1350万美元里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2651413669","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651413669?lang=zh_cn&edition=full","pubTime":"2026-07-16 12:31","pubTimestamp":1784176297,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1191","IE00B3M56506.USD","03933"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173738811","title":"联邦制药（03933）收到诺和诺德1350万美元UBT251全球II期里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=1173738811","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1173738811?lang=zh_cn&edition=full","pubTime":"2026-07-16 12:05","pubTimestamp":1784174730,"startTime":"0","endTime":"0","summary":"2026年7月16日，联邦制药国际控股有限公司公告称，其附属公司联邦生物科技已于2026年7月15日根据与诺和诺德于2025年3月24日签署的UBT251独家许可协议，收到全球超重或肥胖适应症II期临床试验的里程碑付款1,350万美元。根据该独家许可协议，联邦生物科技有资格在满足若干开发及销售目标后，累计获得最高18亿美元的潜在里程碑付款，并可按相关地区年度净销售额获得分层销售提成。公司表示，本次收款已按协议约定完成，将计入公司财务报表。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03933"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651418741","title":"联邦制药(03933)收取诺和诺德关于UBT251独家许可协议的里程碑付款1350万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2651418741","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651418741?lang=zh_cn&edition=full","pubTime":"2026-07-16 12:05","pubTimestamp":1784174701,"startTime":"0","endTime":"0","summary":"智通财经APP讯，联邦制药(03933)发布公告，于2026年7月15日，联邦生物科技已收取诺和诺德支付的UBT251注射液超重或肥胖适应症全球I期临床里程碑付款1350万美元(扣除丹麦预缴税后)。根据独家许可协议并受其条款和条件约束，联邦生物科技有资格收取最高18亿美元的潜在里程碑付款，视乎达成若干开发和销售里程碑而定，以及可收取基于该地区的年度净销售额计算的分层销售提成。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1468316.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"联邦制药(03933)收取诺和诺德关于UBT251独家许可协议的里程碑付款1350万美元","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00B3M56506.USD","03933","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651187494","title":"联邦制药(03933.HK)收取诺和诺德关于UBT251独家许可协议的里程碑付款1350万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2651187494","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651187494?lang=zh_cn&edition=full","pubTime":"2026-07-16 12:05","pubTimestamp":1784174701,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE00B3M56506.USD","03933","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170510815","title":"联邦制药获诺和诺德支付1350万美元里程碑款项，用于II期UBT251试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1170510815","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1170510815?lang=zh_cn&edition=full","pubTime":"2026-07-16 12:03","pubTimestamp":1784174602,"startTime":"0","endTime":"0","summary":"7月15日，联邦制药宣布，已收到诺和诺德公司就II期UBT251试验支付的一笔1350万美元里程碑款项。此次付款标志着双方在相关药物开发合作中取得了重要进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3M56506.USD","03933","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160265604","title":"联邦制药（03933）多剂量玻璃酸钠滴眼液获国家药监局批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=1160265604","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1160265604?lang=zh_cn&edition=full","pubTime":"2026-07-14 19:36","pubTimestamp":1784028961,"startTime":"0","endTime":"0","summary":"2026年7月14日，联邦制药国际控股有限公司宣布，其全资附属公司珠海联邦制药股份有限公司中山分公司申报的玻璃酸钠滴眼液新规格——0.3%已获中国国家药品监督管理局药品注册批准，药品批准文号为“国药准字 H20269162”。联邦制药现有已上市规格为0.3%的单剂量产品，此次获批新增0.3%多剂量规格。联邦制药亦计划持续推进新产品研发，以提升在医药行业的竞争力和创新能力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03933"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651170597","title":"联邦制药(03933.HK)：玻璃酸钠滴眼液新规格获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2651170597","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651170597?lang=zh_cn&edition=full","pubTime":"2026-07-14 19:17","pubTimestamp":1784027869,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["03933","BK1191","IE00B3M56506.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116862052","title":"联邦制药旗下他达拉非片（5mg、10mg、20mg）获准在中国上市","url":"https://stock-news.laohu8.com/highlight/detail?id=1116862052","media":"投资观察","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1116862052?lang=zh_cn&edition=full","pubTime":"2026-07-07 16:47","pubTimestamp":1783414020,"startTime":"0","endTime":"0","summary":"7月2日（路透社）——联邦制药（United Laboratories International Holdings Ltd，03933.HK）宣布，其生产的他达拉非片（规格为5毫克、10毫克和20毫克）已获得中国国家药品监督管理局的上市批准。\n这一批准标志着该产品正式获准在中国市场进行销售。他达拉非是一种用于治疗勃起功能障碍的处方药物，此次获批的三种剂量规格将为医生和患者提供更灵活的治疗选择。\n公司表示，此次获批将有助于进一步丰富其产品管线，并有望在未来为其业绩带来积极贡献。市场分析人士指出，该产品在中国市场的上市，可能会对相关领域的竞争格局产生一定影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03933","BK1191","IE00B3M56506.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.tul.com.cn","stockEarnings":[{"period":"1week","weight":0.0333},{"period":"1month","weight":-0.0228},{"period":"3month","weight":0.0374},{"period":"6month","weight":-0.2473},{"period":"1year","weight":-0.4423},{"period":"ytd","weight":-0.198}],"compareEarnings":[{"period":"1week","weight":0.0355},{"period":"1month","weight":0.0449},{"period":"3month","weight":0.0158},{"period":"6month","weight":-0.0153},{"period":"1year","weight":0.036},{"period":"ytd","weight":0.0148}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"联邦制药国际控股有限公司是一家投资控股公司，主要从事销售中间体产品、原料药及制剂产品业务。该公司通过三个业务部门运营业务。中间体部从事销售中间体产品业务。原料药部从事销售原料药业务。制剂产品部从事销售抗生素制剂产品、非抗生素制剂产品及空心胶囊业务。该公司通过其子公司还从事制造及销售有机化肥业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.368421,"avgChangeRate":-0.033072},{"month":2,"riseRate":0.736842,"avgChangeRate":0.075941},{"month":3,"riseRate":0.631579,"avgChangeRate":0.024557},{"month":4,"riseRate":0.578947,"avgChangeRate":0.075619},{"month":5,"riseRate":0.631579,"avgChangeRate":0.035298},{"month":6,"riseRate":0.263158,"avgChangeRate":-0.013942},{"month":7,"riseRate":0.55,"avgChangeRate":0.015909},{"month":8,"riseRate":0.5,"avgChangeRate":0.024683},{"month":9,"riseRate":0.421053,"avgChangeRate":-0.006976},{"month":10,"riseRate":0.631579,"avgChangeRate":-0.000878},{"month":11,"riseRate":0.473684,"avgChangeRate":-0.023224},{"month":12,"riseRate":0.421053,"avgChangeRate":0.011203}],"exchange":"SEHK","name":"联邦制药","nameEN":"UNITED LAB"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"联邦制药(03933)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供联邦制药(03933)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"联邦制药,03933,联邦制药股票,联邦制药股票老虎,联邦制药股票老虎国际,联邦制药行情,联邦制药股票行情,联邦制药股价,联邦制药股市,联邦制药股票价格,联邦制药股票交易,联邦制药股票购买,联邦制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"联邦制药(03933)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供联邦制药(03933)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}